children who developed HUS after HSCT, and we examined the predisposing factors in children who underwent HSCT for various malignancies. Patient characteristics are summarized in Table 1 . The median age at the time of HSCT was 7 years (range 1-16 By multivariate analysis using logistic regression, neuroblastoma and use of total body irradiation (TBI) years), and the median interval from diagnosis to HSCT was 8 months (range 1-146 months). There were 78 as a conditioning regimen were significant contributing factors for HUS (P = 0.0001 and 0.036, respectively
, but no patients received mitomycin C, which is spread use of hematopoietic stem cell transplantation known to induce HUS. 15 The pretransplant conditioning (HSCT) for patients with hematologic malignancies or solid regimens included melphalan (L-PAM, 180-210 mg/m 2 ) or tumors, HUS has now been recognized as one of the late cyclophosphamide (120-200 mg/kg) combined with busulcomplications after HSCT. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Both cyclosporin A (CsA) phan (4 mg/kg or 140 mg/m 2 × 4 days) or TBI (10-12 Gy, and cytomegalovirus (CMV) infection have been associated except for one patient who received 15 Gy). Agents such with the development of HUS in some reports. [3] [4] [5] [6] Other as etoposide or cytosine arabinoside were added to the constudies found that total body irradiation (TBI) was an ditioning regimens in high-risk patients. important contributing factor to the development of Following HSCT, all patients were monitored closely HUS. [9] [10] [11] [12] with blood and urine examinations for at least 3 months In this study, we report the presentation and outcome of and then were monitored at 1 month intervals after discharge. HUS was diagnosed according to clinical and laboratory criteria as previously described: 11 (1) a sudden and (lasting a minimum of 3 weeks) concomitant with (2) a 282 units) were required in nine of 10 patients. Platelet transfusions were required in three patients. Eight patients were ALL = acute lymphoblastic leukemia; AML = acute myelogenous leuketreated with prednisolone; two patients were not treated. dialysis. Predisposing factors for the development of HUS were examined by univariate analysis (Table 4 ). An underlying sudden and persistent increase in serum lactate dehydrogendiagnosis of neuroblastoma was a significant predisposing ase (LDH) and blood urea nitrogen (BUN) or creatinine in factor for HUS (P Ͻ 0.0001). A history of CDDP administhe face of (3) negative direct and indirect antiglobulin tests tration was another significant factor (P Ͻ 0.0001), but and disseminated intravascular coagulation screens. In there was also a strong correlation between the presence of addition, most patients had a low serum haptoglobin, neuroblastoma and CDDP administration; specifically 23 of microangiopathic changes on peripheral blood smear, and 24 patients with neuroblastoma had received CDDP. Age abnormal urinalyses.
at HSCT and the use of TBI or L-PAM as conditioning We statistically analyzed predisposing factors for the regimens were not statistically significant factors by unidevelopment of HUS. Underlying diagnosis, gender, age at variate analysis (P = 0.10, P = 0.09 and P = 0.13, HSCT, interval from diagnosis to HSCT, type of HSCT, respectively). Gender, interval from diagnosis to HSCT and use of TBI and L-PAM as conditioning regimens, use of type of HSCT had no correlation with the development of CsA as GVHD prophylaxis, acute and chronic GVHD, HUS (P = 1.00, P = 0.75, and P = 0.50, respectively). No CMV infection, and history of CDDP administration were patients with HUS developed acute or chronic GVHD, and evaluated. Univariate analysis was performed by Fisher's none had clinical symptoms of CMV infection after HSCT. exact test. All factors associated with the risk of HUS by By multivariate analysis, factors associated with the risk univariate analysis with P р 0.2 were examined by multiof HUS were examined (Table 5 ). The underlying diagnosis variate analysis using a logistic regression procedure.
of neuroblastoma was the most significant predisposing factor for HUS (odds ratio 32.9, P = 0.0001). TBI as a conditioning regimen also had a significant correlation with Results HUS (odds ratio 10.8, P = 0.036). A history of CDDP administration could not be evaluated in this model, because CDDP was strongly associated with neuroblastoma HUS developed in 10 of 193 evaluable patients, and the clinical characteristics of patients with HUS are summar-(P Ͻ 0.0001). HSCT = hematopoietic stem cell transplantation; GVHD = graft-versus-host disease; CDDP = cisplatin; ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; NB = neuroblastoma; CR1 = 1st complete remission; CR2 = 2nd complete remission; Allo = allogeneic; Auto = autologous; BMT = bone marrow transplantation; PBST = peripheral blood stem cell transplantation; TBI = total body irradiation; L-PAM = melphalan; BU = busulphan; VP-16 = etoposide; CBDCA = carboplatin; MTX = methotrexate.
Discussion chronic GVHD; none received CsA as prophylaxis for GVHD. Moreover, CMV infection in this study was not correlated with HUS since none of our patients had CMV We retrospectively investigated 193 pediatric patients who underwent HSCT to reveal the clinical characteristics and infection before the onset of HUS. TBI had been thought to be one of the most significant outcome of patients with HUS following HSCT and to discern the predisposing factors for the development of HUS.
factors in the development of HUS; most patients had received TBI in previous reports, and the clinical features In previous reports, the prognosis for patients with HUS was very poor; many had progressive disease and died of HUS may be indistinguishable from radiation nephritis. [16] [17] [18] In our study, nine of 10 HUS patients received despite intensive treatment such as plasma exchange. 12, 13 However, there is one report in which all patients survived TBI. Multivariate analysis identified TBI as a significant predisposing factor for HUS. However, the underlying without life-threatening sequelae. 11 In our study, pericardial effusion and hypertension were not progressive or lifediagnosis of neuroblastoma was most strongly correlated with HUS. Although L-PAM is a nephrotoxic agent, and threatening; hemolysis and all symptoms resolved within 2 months without plasma exchange. Seven patients are alive all 10 patients received L-PAM, it was not a significant factor by multivariate analysis because of its strong correwithout any sequelae 5-69 months (median 29 months) following the onset of HUS. Three other patients continue to lation with TBI (P = 0.001). Similarly, although younger patients had a greater tendency to develop HUS than older have mild renal dysfunction 21-28 months after the onset of HUS, but none have required dialysis. Although eight patients, age at HSCT had no significant correlation with HUS by multivariate analysis, possibly because of its strong patients treated with prednisolone had their hemolysis resolve within 1-2 months, it is uncertain whether prednisocorrelation with the underlying diagnosis (P Ͻ 0.0001). In fact, most patients with neuroblastoma were younger than lone contributed to the resolution of hemolysis and the relatively good prognosis.
8 years of age. Why is the incidence of HUS higher in patients with The incidence of HUS following HSCT has been estimated to be 0.8-9.5% in adult patients. [11] [12] [13] In pediatric neuroblastoma? Most patients with neuroblastoma received CDDP before HSCT. Although intraoperative irradiation of patients, Guinan et al 10 reported a higher incidence (45%) of HUS after HSCT, particularly in patients with neuroblasthe primary site and nephrectomy may be risk factors, HUS developed in three of eight patients who did not receive toma (seven of 10). In our pediatric patients, the incidence of HUS in all patients was 5.2% (10 of 193), similar to the intraoperative irradiation and in four of 15 patients not receiving nephrectomy. It is well documented that CDDP adult series. In patients with neuroblastoma, however, seven of 24 (29%) developed HUS, consistent with the high has strong nephrotoxicity and has been associated with HUS. 19, 20 We suspect that a history of CDDP adminisincidence reported by Guinan.
In previous reports, possible risk factors for HUS after tration is one explanation of the higher incidence of HUS in patients with neuroblastoma. HSCT included CsA, 3-5 GVHD, 6 CMV infection 6 and TBI. 9 However, none were statistically defined as single Because the clinical features of HUS may be indistinguishable from radiation nephritis, we suspect that the predisposing factors for HUS; thus the etiology of HUS was considered to be multifactorial. [10] [11] [12] In our 10 patients, cause of HUS in most cases following HSCT may be radiation nephritis. We also suspect that radiation nephrotoxicfive received allogeneic HSCT, and none had acute or Table 3 Clinical presentation, treatment and outcome of 10 patients with hemolytic uremic syndrome ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma; HD = Hodgkin's disease; HSCT = hematopoietic stem cell transplantation; TBI = total body irradiation; L-PAM = melphalan; CDDP = cisplatin.
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